ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Kazuhiro Yanagihara
Hiromi Wada
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, F.
Right arrow Articles by Wada, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, F.
Right arrow Articles by Wada, H.

Ann Thorac Surg 1998;66:1745-1750
© 1998 The Society of Thoracic Surgeons

Original articles: general thoracic

Lewis Y antigen expression and postoperative survival in non–small cell lung cancer

Fumihiro Tanaka, MDa, Ryo Miyahara, MDa, Yohsuke Ohtake, MDa, Kazuhiro Yanagihara, MDa, Tatsuo Fukuse, MDa, Shigeki Hitomi, MDa, Hiromi Wada, MDa

a Department of Thoracic Surgery, Chest Disease Research Institute, Kyoto University Kyoto, Japan

Address reprint requests to Dr Wada, Department of Thoracic Surgery, Chest Disease Research Institute, Kyoto University, Shogoinn-kawahara-cho 53, Sakyo-ku, Kyoto 606, Japan
e-mail: (wada{at}chest.kyoto-u.ac.jp)

Presented at the Poster session of the Thirty-fourth Annual Meeting of The Society of Thoracic Surgeons, New Orleans, LA, Jan 26–28, 1998.

Background. In contrast to other Lewis blood group-related antigens, Lewis Y antigen (LeY) has not been fully investigated in non–small cell lung cancer.

Methods. To assess the significance of LeY expression, 236 patients with completely resected pathologic stage 1-3a were reviewed with immunohistochemical analysis.

Results. LeY expression was positive in 179 patients (75.8%). In poorly differentiated cancer, percentage of LeY-positive patients was lower than in moderately to well-differentiated cancer (67.2% versus 81.2%, p = 0.028). Five-year survival rate of LeY-positive patients was 78.2%, significantly higher than that of LeY-negative patients (59.7%, p = 0.001). Combined with p53 status, differences in survival proved to be marked; 5-year survival rate of patients with positive LeY expression and without aberrant p53 expression, was as high as 83.3%, whereas that of patients with negative LeY expression and with aberrant p53 expression was only 38.4% (p < 0.001). Multivariate analysis confirmed that LeY expression was a significant independent factor to predict better survival.

Conclusions. LeY expression is a significant prognostic factor related to grade of cancer differentiation.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Ishikawa, T. Nakagawa, R. Miyahara, Y. Kawano, K. Takenaka, K. Yanagihara, Y. Otake, H. Katakura, H. Wada, and F. Tanaka
Expression of MDA-7/IL-24 and Its Clinical Significance in Resected Non-Small Cell Lung Cancer
Clin. Cancer Res., February 1, 2005; 11(3): 1198 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Shoji, F. Tanaka, T. Takata, K. Yanagihara, Y. Otake, N. Hanaoka, R. Miyahara, T. Nakagawa, Y. Kawano, S. Ishikawa, et al.
Clinical Significance of p21 Expression in Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 15, 2002; 20(18): 3865 - 3871.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. D. Brundage, D. Davies, and W. J. Mackillop
Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress
Chest, September 1, 2002; 122(3): 1037 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Yuan, C.-J. Yu, K.-T. Luh, S.-H. Kuo, Y.-C. Lee, and P.-C. Yang
Aberrant p53 Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 15, 2002; 20(4): 900 - 910.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
Eur. Respir. J., October 1, 2001; 18(4): 705 - 719.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
M. Dettke, G. Pálfi, and H. Loibner
Activation-dependent expression of the blood group-related Lewis Y antigen on peripheral blood granulocytes
J. Leukoc. Biol., October 1, 2000; 68(4): 511 - 514.
[Abstract] [Full Text]

Home page
 JCOHome page
F. Tanaka, Y. Kawano, M. Li, T. Takata, R. Miyahara, K. Yanagihara, Y. Ohtake, T. Fukuse, and H. Wada
Prognostic Significance of Apoptotic Index in Completely Resected Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 1, 1999; 17(9): 2728 - 2728.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1998 by The Society of Thoracic Surgeons.